Asset profile
LY03003
Small molecule
Evidence outlook · lead readout
NCT04571164 · Parkinson Disease
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT04571164: The trial randomized 294 participants to LY03003 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in the clinical UPDRS parts II+III score over 24 weeks, but the primary comparison and safety findings are not available, preventing assessment of whether the endpoint was met.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 18 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| LY03003: this drug | Phase 3 | Small molecule | dopamine | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Rotigotine (Neupro) | Approved | Small molecule | dopamine | ||
| LY03009 | Phase 1 | Small molecule | dopamine | ||
| SER-252 (PEOZ-Apomorphine) | Phase 1 | Small molecule | dopamine | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | ||
| Entacapone (Comtess) | Approved | Small molecule | COMT | ||
| Foslevodopa / Foscarbidopa (Vyalev) | Approved | Small molecule | dopamine precursor | ||
| Inbrija (CVT-301) | Approved | Small molecule | dopamine precursor | ||
| Istradefylline (Nourianz) | Approved | Small molecule | adenosine A2A | ||
| Levodopa-Carbidopa Intestinal Gel (Duopa) | Approved | Small molecule | dopamine precursor | ||
| Opicapone (Ongentys) | Approved | Small molecule | COMT, PDE4 | ||
| Parcopa | Approved | Small molecule | dopamine precursor | ||
| Pimavanserin (Nuplazid) | Approved | Small molecule | 5-HT2A/2C receptor, Serotonin 5-HT2A receptor (antagonist / inverse agonist) |
…and 50 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.